Rockwell Medical, Inc. (RMTI)

Over the past six months (October 2025 - April 2026), Rockwell Medical, Inc.'s stock price has been impacted by several events. As of March 27, 2026, the company's share price was $0.87, a 22.99% decline from March 31, 2025. Key events include financial results announcements, customer base changes and agreements, operational adjustments, and product portfolio expansion. The company announced its Third Quarter 2025 results on November 12, 2025, and its Fourth Quarter and Full-Year 2025 results on March 26, 2026, highlighting profitability on an Adjusted EBITDA basis for the second consecutive year in 2025 and generating positive cash flow from operating activities in Q4 2025. In December 2025, Rockwell Medical extended its product purchase agreement with one of the largest dialysis providers in the United States through December 31, 2026, with increased product pricing. In 2025, Rockwell Medical made internal adjustments to align its infrastructure with demand, which contributed to a strong gross margin of 21% in Q4 2025, and ended manufacturing at its South Carolina facility to streamline costs. In February 2025, Rockwell Medical added a single-use bicarbonate cartridge to its hemodialysis concentrates product portfolio.

The provided search results do not indicate any specific demand seasonality for Rockwell Medical, Inc.'s products and services. The company's hemodialysis products are vital to vulnerable patients with end-stage kidney disease, suggesting a consistent and ongoing demand driven by medical necessity rather than seasonal fluctuations. The nature of end-stage renal disease treatment typically requires continuous dialysis, implying a stable demand throughout the year.

Rockwell Medical, Inc., founded in 1996 and headquartered in Wixom, Michigan, is a publicly traded healthcare company specializing in the development, manufacturing, commercialization, and distribution of hemodialysis products globally. It is a leading supplier of liquid bicarbonate concentrates and the second-largest supplier of acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's major products include a portfolio of hemodialysis concentrates and ancillary products crucial for sustaining the lives of patients undergoing dialysis. Rockwell Medical previously commercialized Triferic, but its U.S. commercialization has been discontinued in favor of international partnerships. In February 2025, Rockwell Medical expanded its product portfolio by adding a single-use bicarbonate cartridge.

Rockwell Medical has a significant global presence, manufacturing its hemodialysis concentrates in facilities located in Iowa, Michigan, Minnesota, South Carolina, and Texas within the United States. The company distributes its hemodialysis concentrates products to dialysis providers worldwide, with a growing international business that accounts for approximately 10% of its total revenue. Its products are sold in numerous countries across North America, South America, Asia, and Africa, including the United States, Bahamas, Barbados, Belize, Bermuda, Botswana, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Ethiopia, Ghana, Grenada, Guam, Guatemala, Honduras, Jamaica, Mongolia, Namibia, Nicaragua, Pakistan, Peru, Philippines, Puerto Rico, South Africa, St. Lucia, Trinidad & Tobago, U.S. Virgin Islands, United Arab Emirates, and Vietnam.

Rockwell Medical has cultivated a strong brand reputation, particularly in terms of quality, reliability, and customer service within the hemodialysis community. The company emphasizes providing high-quality products controlled by a robust Quality Management System regulated by the U.S. Food and Drug Administration (FDA), and it is ISO 13485 Certified, adhering to current Good Manufacturing Practices (cGMP) and Association for Advancement of Medical Instrumentation (AAMI) standards. Rockwell Medical has been certified as a "Great Place to Work" for four consecutive years (2023-2026) and was named a "Fortune Best Workplaces in Manufacturing & Production™" in 2024 and 2025.

Rockwell Medical, Inc.'s ownership structure includes institutional, insider, and retail investors. Approximately 4.39% to 7.52% of the company's stock is owned by institutional investors, 13.39% by insiders, and around 79.09% by public companies and individual investors. Major institutional owners and shareholders include Vanguard Group Inc., Renaissance Technologies Llc., Geode Capital Management, Llc., BlackRock, Inc., UBS Group AG, Northern Trust Corp., Jane Street Group, Llc., State Street Corp., HighTower Advisors, LLC., Citadel Advisors Llc., Armistice Capital LLC., XTX Topco Ltd., GSA Capital Partners LLP, and Globeflex Capital L P. The Irrevocable Larson Family Investment Trust owns the most shares of Rockwell Medical.